Daewoong Pharmaceutical's 'Hoistar Tablets' Approved for Combined Phase 2 and 3 Clinical Trials for COVID-19

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 17th that it will change the Phase 2 clinical trial of 'Hoista Tablets,' being developed as a treatment for the novel coronavirus infection (COVID-19), to a Phase 2/3 clinical trial. This follows the approval from the Ministry of Food and Drug Safety to change the Phase 2 trial to a Phase 2/3 trial.

Daewoong Pharmaceutical received approval to combine Phase 3 with the existing Phase 2, enabling rapid research involving a large number of patients. This clinical trial will be conducted on approximately 1,000 patients with mild to moderate COVID-19.

Hoista Tablets are prescription drugs approved for the treatment of chronic pancreatitis and postoperative reflux esophagitis. Daewoong Pharmaceutical is developing it as the first oral COVID-19 treatment in Korea. Recently, its effectiveness was confirmed through off-label prescriptions to actual COVID-19 patients.

Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said, "If Hoista Tablets are developed as a COVID-19 treatment, mild patients will be able to self-treat by taking Hoista Tablets without needing to visit a hospital," adding, "We will do our best to quickly secure clinical results with the goal of launching in January next year."

This content was produced with the assistance of AI translation services.